Loading…
Measurement of complexed PSA improves specificity for early detection of prostate cancer
Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for im...
Saved in:
Published in: | Urology (Ridgewood, N.J.) N.J.), 1998-09, Vol.52 (3), p.372-378 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023 |
---|---|
cites | cdi_FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023 |
container_end_page | 378 |
container_issue | 3 |
container_start_page | 372 |
container_title | Urology (Ridgewood, N.J.) |
container_volume | 52 |
creator | Brawer, Michael K. Meyer, Grant E. Letran, Jason L. Bankson, Dan D. Morris, Deborah L. Yeung, Kwok K. Allard, W.Jeffrey |
description | Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for improved specificity. Of all these approaches, the free/total PSA ratio appears to be the most promising. Given that most circulating PSA is complexed to alpha
1-antichymotrypsin, and that this moiety represents a greater proportion of the total PSA in those men with carcinoma, we set out to determine whether complexed PSA would improve specificity in the detection of men with prostate cancer.
Methods. Archival sera were obtained from 300 men, 75 of whom had biopsy-proved prostate cancer. All sera had been previously stored at −70°C for variable periods. An investigative assay for complexed PSA (Bayer) was used. The Tandem-R free and total PSA assays (Hybritech) were used according to the manufacturer’s recommendations.
Results. Among all patients, specificities for the total PSA, free/total PSA, and complexed PSA alone were 21.8%, 15.6%, and 26.7%, respectively, at cutoffs yielding 95% sensitivity. Similar equivalence or superior performance, in terms of specificity relative to the free/total PSA ratio, was seen at other sensitivity thresholds and other total PSA ranges.
Conclusions. Complexed PSA alone performs better than total PSA or the free/total PSA ratio and obviates the need for a second analyte determination. We believe this marker may offer significant enhancement in PSA testing with significant economic advantages. |
doi_str_mv | 10.1016/S0090-4295(98)00241-6 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73889951</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090429598002416</els_id><sourcerecordid>73889951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMoWi-PIGQhoovRk2QmM1lJEW-gKFTBXchkTiAy06nJtNi3N7WlW1dncb7_XD5CThlcMWDyegKgIMu5Ki5UdQnAc5bJHTJiBS8zpVSxS0Zb5IAcxvgFAFLKcp_sq1JAnssR-XxBE-cBO5wOtHfU9t2sxR9s6NtkTH03C_0CI40ztN5564cldX2gaEK7pA0OaAffT1fJRMbBDEitmVoMx2TPmTbiyaYekY_7u_fbx-z59eHpdvyc2ZxVQ1YYUEYIcC5vhGxyVFxhKZ2QquA1g1qgcpaLmjsoSmmRJcJwBGNqoYCLI3K-npv2f88xDrrz0WLbmin286hLUVVJBktgsQZtOjQGdHoWfGfCUjPQK6P6z6he6dKq0n9GtUy5082Ced1hs01tFKb-2aZvojWtC-l9H7cYF1UpyjxhN2sMk4yFx6Cj9ZhMNT4kibrp_T-H_ALX55Ly</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73889951</pqid></control><display><type>article</type><title>Measurement of complexed PSA improves specificity for early detection of prostate cancer</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Brawer, Michael K. ; Meyer, Grant E. ; Letran, Jason L. ; Bankson, Dan D. ; Morris, Deborah L. ; Yeung, Kwok K. ; Allard, W.Jeffrey</creator><creatorcontrib>Brawer, Michael K. ; Meyer, Grant E. ; Letran, Jason L. ; Bankson, Dan D. ; Morris, Deborah L. ; Yeung, Kwok K. ; Allard, W.Jeffrey</creatorcontrib><description>Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for improved specificity. Of all these approaches, the free/total PSA ratio appears to be the most promising. Given that most circulating PSA is complexed to alpha
1-antichymotrypsin, and that this moiety represents a greater proportion of the total PSA in those men with carcinoma, we set out to determine whether complexed PSA would improve specificity in the detection of men with prostate cancer.
Methods. Archival sera were obtained from 300 men, 75 of whom had biopsy-proved prostate cancer. All sera had been previously stored at −70°C for variable periods. An investigative assay for complexed PSA (Bayer) was used. The Tandem-R free and total PSA assays (Hybritech) were used according to the manufacturer’s recommendations.
Results. Among all patients, specificities for the total PSA, free/total PSA, and complexed PSA alone were 21.8%, 15.6%, and 26.7%, respectively, at cutoffs yielding 95% sensitivity. Similar equivalence or superior performance, in terms of specificity relative to the free/total PSA ratio, was seen at other sensitivity thresholds and other total PSA ranges.
Conclusions. Complexed PSA alone performs better than total PSA or the free/total PSA ratio and obviates the need for a second analyte determination. We believe this marker may offer significant enhancement in PSA testing with significant economic advantages.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/S0090-4295(98)00241-6</identifier><identifier>PMID: 9730446</identifier><identifier>CODEN: URGYAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Humans ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Retrospective Studies ; Sensitivity and Specificity ; Time Factors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Urology (Ridgewood, N.J.), 1998-09, Vol.52 (3), p.372-378</ispartof><rights>1998 Elsevier Science Inc.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023</citedby><cites>FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2387374$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9730446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brawer, Michael K.</creatorcontrib><creatorcontrib>Meyer, Grant E.</creatorcontrib><creatorcontrib>Letran, Jason L.</creatorcontrib><creatorcontrib>Bankson, Dan D.</creatorcontrib><creatorcontrib>Morris, Deborah L.</creatorcontrib><creatorcontrib>Yeung, Kwok K.</creatorcontrib><creatorcontrib>Allard, W.Jeffrey</creatorcontrib><title>Measurement of complexed PSA improves specificity for early detection of prostate cancer</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for improved specificity. Of all these approaches, the free/total PSA ratio appears to be the most promising. Given that most circulating PSA is complexed to alpha
1-antichymotrypsin, and that this moiety represents a greater proportion of the total PSA in those men with carcinoma, we set out to determine whether complexed PSA would improve specificity in the detection of men with prostate cancer.
Methods. Archival sera were obtained from 300 men, 75 of whom had biopsy-proved prostate cancer. All sera had been previously stored at −70°C for variable periods. An investigative assay for complexed PSA (Bayer) was used. The Tandem-R free and total PSA assays (Hybritech) were used according to the manufacturer’s recommendations.
Results. Among all patients, specificities for the total PSA, free/total PSA, and complexed PSA alone were 21.8%, 15.6%, and 26.7%, respectively, at cutoffs yielding 95% sensitivity. Similar equivalence or superior performance, in terms of specificity relative to the free/total PSA ratio, was seen at other sensitivity thresholds and other total PSA ranges.
Conclusions. Complexed PSA alone performs better than total PSA or the free/total PSA ratio and obviates the need for a second analyte determination. We believe this marker may offer significant enhancement in PSA testing with significant economic advantages.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Retrospective Studies</subject><subject>Sensitivity and Specificity</subject><subject>Time Factors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKAzEUhoMoWi-PIGQhoovRk2QmM1lJEW-gKFTBXchkTiAy06nJtNi3N7WlW1dncb7_XD5CThlcMWDyegKgIMu5Ki5UdQnAc5bJHTJiBS8zpVSxS0Zb5IAcxvgFAFLKcp_sq1JAnssR-XxBE-cBO5wOtHfU9t2sxR9s6NtkTH03C_0CI40ztN5564cldX2gaEK7pA0OaAffT1fJRMbBDEitmVoMx2TPmTbiyaYekY_7u_fbx-z59eHpdvyc2ZxVQ1YYUEYIcC5vhGxyVFxhKZ2QquA1g1qgcpaLmjsoSmmRJcJwBGNqoYCLI3K-npv2f88xDrrz0WLbmin286hLUVVJBktgsQZtOjQGdHoWfGfCUjPQK6P6z6he6dKq0n9GtUy5082Ced1hs01tFKb-2aZvojWtC-l9H7cYF1UpyjxhN2sMk4yFx6Cj9ZhMNT4kibrp_T-H_ALX55Ly</recordid><startdate>19980901</startdate><enddate>19980901</enddate><creator>Brawer, Michael K.</creator><creator>Meyer, Grant E.</creator><creator>Letran, Jason L.</creator><creator>Bankson, Dan D.</creator><creator>Morris, Deborah L.</creator><creator>Yeung, Kwok K.</creator><creator>Allard, W.Jeffrey</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980901</creationdate><title>Measurement of complexed PSA improves specificity for early detection of prostate cancer</title><author>Brawer, Michael K. ; Meyer, Grant E. ; Letran, Jason L. ; Bankson, Dan D. ; Morris, Deborah L. ; Yeung, Kwok K. ; Allard, W.Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Retrospective Studies</topic><topic>Sensitivity and Specificity</topic><topic>Time Factors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brawer, Michael K.</creatorcontrib><creatorcontrib>Meyer, Grant E.</creatorcontrib><creatorcontrib>Letran, Jason L.</creatorcontrib><creatorcontrib>Bankson, Dan D.</creatorcontrib><creatorcontrib>Morris, Deborah L.</creatorcontrib><creatorcontrib>Yeung, Kwok K.</creatorcontrib><creatorcontrib>Allard, W.Jeffrey</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brawer, Michael K.</au><au>Meyer, Grant E.</au><au>Letran, Jason L.</au><au>Bankson, Dan D.</au><au>Morris, Deborah L.</au><au>Yeung, Kwok K.</au><au>Allard, W.Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measurement of complexed PSA improves specificity for early detection of prostate cancer</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>1998-09-01</date><risdate>1998</risdate><volume>52</volume><issue>3</issue><spage>372</spage><epage>378</epage><pages>372-378</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><coden>URGYAZ</coden><abstract>Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for improved specificity. Of all these approaches, the free/total PSA ratio appears to be the most promising. Given that most circulating PSA is complexed to alpha
1-antichymotrypsin, and that this moiety represents a greater proportion of the total PSA in those men with carcinoma, we set out to determine whether complexed PSA would improve specificity in the detection of men with prostate cancer.
Methods. Archival sera were obtained from 300 men, 75 of whom had biopsy-proved prostate cancer. All sera had been previously stored at −70°C for variable periods. An investigative assay for complexed PSA (Bayer) was used. The Tandem-R free and total PSA assays (Hybritech) were used according to the manufacturer’s recommendations.
Results. Among all patients, specificities for the total PSA, free/total PSA, and complexed PSA alone were 21.8%, 15.6%, and 26.7%, respectively, at cutoffs yielding 95% sensitivity. Similar equivalence or superior performance, in terms of specificity relative to the free/total PSA ratio, was seen at other sensitivity thresholds and other total PSA ranges.
Conclusions. Complexed PSA alone performs better than total PSA or the free/total PSA ratio and obviates the need for a second analyte determination. We believe this marker may offer significant enhancement in PSA testing with significant economic advantages.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9730446</pmid><doi>10.1016/S0090-4295(98)00241-6</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-4295 |
ispartof | Urology (Ridgewood, N.J.), 1998-09, Vol.52 (3), p.372-378 |
issn | 0090-4295 1527-9995 |
language | eng |
recordid | cdi_proquest_miscellaneous_73889951 |
source | Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list) |
subjects | Aged Aged, 80 and over Biological and medical sciences Humans Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Retrospective Studies Sensitivity and Specificity Time Factors Tumors of the urinary system Urinary tract. Prostate gland |
title | Measurement of complexed PSA improves specificity for early detection of prostate cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-09T03%3A46%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measurement%20of%20complexed%20PSA%20improves%20specificity%20for%20early%20detection%20of%20prostate%20cancer&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Brawer,%20Michael%20K.&rft.date=1998-09-01&rft.volume=52&rft.issue=3&rft.spage=372&rft.epage=378&rft.pages=372-378&rft.issn=0090-4295&rft.eissn=1527-9995&rft.coden=URGYAZ&rft_id=info:doi/10.1016/S0090-4295(98)00241-6&rft_dat=%3Cproquest_cross%3E73889951%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73889951&rft_id=info:pmid/9730446&rfr_iscdi=true |